<p>The goal was to evaluate the potential impact of pharmacogenomic testing on drug prescribing over a lifetime. To address this goal, 300 random patients enrolled in Marshfield Clinic's <a href="https://www.marshfieldresearch.org/cpmr/pmrp">PMRP biobank</a> with life-long medical records were whole genome sequenced and evaluated for known clinically actionable pharmacogenomic variants as defined by CPIC and FDA. This genomic data was evaluated in the context of extensive longitudinal prescription record data from patient EHR. Results show nearly all (93%) carry a clinically actionable pharmacogenomic variant and 80% with a variant were prescribed approximately three medications on average that may have been impacted because of their variants, the optimal age for pharmacogenomic testing was prior to age 50, but most patients well past their 50s can still benefit from pharmacogenomic testing. Results available include genotype and drug prescribing data.</p>

Estimating the Efficacy of Pharmacogenomics Over a Lifetime

Pharmacogenetics study with SNP/CNV Genotypes (NGS) data on dbGaP (300 participants)

Estimating the Efficacy of Pharmacogenomics Over a Lifetime

Description

Applying For Access

Summary